Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARBIOS SYSTEMS, INC.	-93.90%	-.--%	-	-	50
ABBOTT LABORATORIES	+3.13%	+0.12%	-31.92%	-16.03%	153B
MEDTRONIC PLC	+1.17%	-1.19%	-6.53%	-8.15%	101B
HOYA CORPORATION	-1.82%	-0.54%	+56.86%	+55.61%	55.9B
CENCORA, INC.	+3.63%	+0.34%	-3.66%	+50.48%	52.78B
BECTON, DICKINSON AND COMPANY	+2.99%	+0.07%	-14.41%	-43.38%	38.77B
MEDLINE INC.	+1.84%	-4.81%	-	-	29.35B
DEXCOM, INC.	+0.46%	-5.06%	-13.00%	-45.20%	26.65B
WEST PHARMACEUTICAL SERVICES, INC.	+1.08%	+1.27%	+54.02%	-9.06%	23.29B
TERUMO CORPORATION	-2.25%	-1.92%	-16.37%	-5.76%	20.51B
Average	-8.34%	-2.36%	+3.12%	-2.69%	55.75B
Weighted average by Cap.	+1.72%	-1.78%	-5.38%	-1.53%

See all sector performances

Arbios Systems, Inc. (Arbios) is a medical device and cell-therapy company focused on the development of products for the treatment of liver failure. The Company's lead product candidates under development consist of a extracorporeal blood purification therapy called the SEPET Liver Assist Device and an extracorporeal, bioartificial liver therapy referred to as the HepatAssist Cell-Based Liver Support System that incorporate porcine pig liver cells. In October 2008, Arbios announced that it has sold all its rights and interest in its bioartificial liver system, HepatAssist, to HepaLife Technologies, Inc. On January 9, 2009, Arbios announced that it filed for protection under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company